A pivotal publication on January 1, 2019, detailed a study comparing risankizumab (Skyrizi) with adalimumab for patients with moderate-to-severe plaque psoriasis. This publication provides key insights into the comparative profile of these two treatments.
Background
Risankizumab (Skyrizi) is a biologic therapy used in the treatment of various inflammatory conditions, including moderate-to-severe plaque psoriasis. This pivotal study compared risankizumab to adalimumab, another established biologic, in patients suffering from this chronic skin condition.
Trial design
The published study, known as IMMvent, was a randomised, double-blind, active-comparator-controlled trial. It was designed to evaluate risankizumab against adalimumab in patients diagnosed with moderate-to-severe plaque psoriasis.
What this means
The publication of this pivotal study provides important comparative data for clinicians and researchers. By directly comparing risankizumab with adalimumab, the study offers valuable context for treatment decisions in patients with moderate-to-severe plaque psoriasis. This type of active-comparator-controlled trial is crucial for understanding the relative benefits and risks of newer therapies against established standards of care.
Source
The information regarding this pivotal publication was sourced from PubMed. The article, titled "Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled p", was published on January 1, 2019, and is available on pubmed.ncbi.nlm.nih.gov.